- Home
- RDHL vs XRTX Comparison
RDHL vs XRTX Comparison
Compare RDHL & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RDHL | XRTX |
|---|---|---|
| Founded | 2009 | 2011 |
| Country | Israel | Canada |
| Employees | N/A | 3 |
| Industry | Biotechnology: Pharmaceutical Preparations | Pharmaceuticals and Biotechnology |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0M | 4.2M |
| IPO Year | 2012 | 2018 |
Fundamental Metrics
Financial Performance| Metric | RDHL | XRTX |
|---|---|---|
| Price | $0.85 | $2.25 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.1M | 8.1K |
| Earning Date | 04-27-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $381.91 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.57 | $0.35 |
| 52 Week High | $2.79 | $3.60 |
Technical Indicators
Market Signals| Indicator | RDHL | XRTX |
|---|---|---|
| Relative Strength Index (RSI) | 68.84 | 48.71 |
| Support Level | $0.76 | $1.99 |
| Resistance Level | $0.91 | $2.29 |
| Average True Range (ATR) | 0.09 | 0.17 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 28.43 | 33.33 |
Price Performance
Historical ComparisonAbout RDHL Redhill Biopharma Ltd.
RedHill Biopharma Ltd is a specialty biopharmaceutical company mainly focused on the U.S. development and commercialization of drugs for GI diseases, infectious diseases, and oncology. The Company is mainly focused on the advancement of its development pipeline of clinical-stage therapeutic candidates and also commercializes its GI-related product, Talicia (omeprazole, amoxicillin, and rifabutin) in the U.S. Its therapeutic candidates include opaganib, RHB-204, RHB-104, RHB-102 (Bekinda), and RHB-107.
About XRTX XORTX Therapeutics Inc.
XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.